Results 21 to 30 of about 18,145 (196)

Ranibizumab and the eye [PDF]

Canadian Medical Association Journal, 2011
Ranibizumab is a recombinant, monoclonal antibody fragment that inhibits vascular endothelial growth factor (known as a VEGF-A inhibitor).1 Because it costs about 10 times more than bevacizumab,2 an anti-VEGF agent approved for intravenous use in metastatic colon cancer, ophthalmologists may ...
Jason, Noble, Varun, Chaudhary
openaire   +2 more sources

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis [PDF]

, 2021
Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.
Meireles, Angelina, Beirão, João Nuno Melo, Pessoa, Bernardete, Figueira, João, Melo Beirão, João Nuno, Figueira, João P, Coelho, João, Monteiro, Sílvia, Coelho, Constança, Beirão, João, Malheiro, Luísa, Carneiro, Inês   +11 more
core   +1 more source

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.

PLoS ONE, 2022
PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama, Riko Matsumoto, Shumpei Obata, Osamu Sawada, Yoshitsugu Saishin, Masashi Kakinoki, Tomoko Sawada, Masahito Ohji   +7 more
doaj   +1 more source

Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis [PDF]

International Journal of Ophthalmology, 2017
AIM: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro.
Wei Wang, Guang-Xu Liu, Yue-Hua Li, Xue-Dong Li, Yan He   +4 more
doaj   +1 more source

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion [PDF]

, 2020
Purpose: Comparing the efficacy of intravitreal injections of bevacizumab to ranibizumab in the treatment of macular edema (ME) resulting from retinal vein occlusion (RVO).
Verbraak, F.D. (Frank), Schauwvlieghe, AME, Hoyng, C.B., Los, LI, Jong-Hesse, Y. de, Hoyng, CB, Vader, M.J.C. (Maartje J.C.), Leeuwen, R. (Redmer) van, Vingerling, Hans, Los, L.I. (Leonoor I.), Schlingemann, RO, Leeuwen, R. Van, van Leeuwen, R, Vingerling, J.R. (Hans), Dijkgraaf, M.G., de Jong-Hesse, Y, Schlingemann, R.O. (Reinier), Dijkman, G., Zwinderman, AH, Hoyng, C.B. (Carel), Lith-Verhoeven, J.J. van, Schlingemann, R.O., van Leeuwen, R., van Lith-Verhoeven, JJC, Vingerling, J.R., Vader, MJC, Verbraak, FD, Peto, T., de Jong-Hesse, Y. (Yvonne), Dijkman, G, Dijkgraaf, M.G.W. (Marcel), Los, L.I., Hooymans, JMM, Lith-Verhoeven, J.J.C. (Janneke) van, Schauwvlieghe, A.M., Schauwvlieghe, ASME, Verbraak, F.D., Zwinderman, A.H. (Ailko), Zwinderman, A.H., de Jong-Hesse, Y., Hooymans, J.M., Peto, T. (Tünde), Hooymans, JM, Vader, M.J.C., Hooymans, J.M.M. (Johanna), Peto, T, Dijkgraaf, MG, Schauwvlieghe, A.M.E. (Ann-Sofie), Dijkgraaf, MGW   +48 more
core   +3 more sources

6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome [PDF]

International Journal of Ophthalmology, 2016
AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis.
Patrick J Chiam, Vivian W Ho, Nicholas M Hickley, Venkat Kotamarthi   +3 more
doaj   +1 more source

One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study [PDF]

International Journal of Ophthalmology, 2018
AIM: To assess the effectiveness and safety of ranibizumab 0.5 mg in Taiwanese patients with polypoidal choroidal vasculopathy (PCV) by performing a retrospective exploratory subgroup analysis of the REAL study.
San-Ni Chen, Cheng-Kuo Cheng, Ling Yeung, Jiann-Torng Chen, Wei-Chun Chan, Jorn-Hon Liu, Shwu-Jiuan Sheu, Wen-Chuan Wu, Chi-Chun Lai   +8 more
doaj   +1 more source

Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. [PDF]

PLoS ONE, 2014
Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the
Paul Mitchell, Neil Bressler, Quan V Doan, Chantal Dolan, Alberto Ferreira, Aaron Osborne, Elena Rochtchina, Mark Danese, Shoshana Colman, Tien Y Wong   +9 more
doaj   +1 more source

Protective effects on the retina after ranibizumab treatment in an ischemia model. [PDF]

PLoS ONE, 2017
Retinal ischemia is common in eye disorders, like diabetic retinopathy or retinal vascular occlusion. The goal of this study was to evaluate the potential protective effects of an intravitreally injected vascular endothelial growth factor (VEGF ...
Stephanie C Joachim, Marina Renner, Jacqueline Reinhard, Carsten Theiss, Caroline May, Stephanie Lohmann, Sabrina Reinehr, Gesa Stute, Andreas Faissner, Katrin Marcus, H Burkhard Dick   +10 more
doaj   +1 more source

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study.

PLoS ONE, 2020
PurposeTo evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS™ study.Patients and methodsLUMINOUS, a 5 ...
Frank G Holz, Angelo M Minnella, Raman Tuli, Pradeepa Yoganathan, Soumil Parikh, Robin Hamilton, LUMINOUS™ study group   +6 more
doaj   +1 more source